MGNX MacroGenics Inc.

10.46
-0.34  -3%
Previous Close 10.8
Open 10.58
Price To Book 2.01
Market Cap 512,102,751
Shares 48,958,198
Volume 99,036
Short Ratio
Av. Daily Volume 566,115
Stock charts supplied by TradingView

NewsSee all news

  1. MacroGenics to Present at the J.P. Morgan Healthcare Conference

    Rockville, MD, Jan. 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  2. MacroGenics Outlines Corporate Priorities for 2020

    Rockville, MD, Jan. 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  3. MacroGenics Announces Submission of Margetuximab Biologics License Application to U.S. FDA

    ROCKVILLE, MD, Dec. 19, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  4. MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

    Rockville, MD, Dec. 11, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  5. MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting

    Rockville, MD, Dec. 09, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 updated data presented at ASH December 9, 2019. CR rate 16%; CR + CRh + CRi 30%.
Flotetuzumab
AML/MDS
BLA filing announced December 19, 2019.
Margetuximab
Metastatic breast cancer
Phase 2/3 trial to be initiated 3Q 2019.
Margetuximab in combination with checkpoint inhibitor
Gastric cancer
Phase 1 data due 2021.
INCMGA0012
Anal cancer
Phase 1 poster presentation at AACR April 1, 2019.
INCMGA0012
Solid tumors
Phase 1 initial data due 2020.
INCMGA0012
Endometrial cancer
Phase 2/3 trial planned.
Enoblituzumab and MGA012
Solid tumors
Phase 1 partial clinical hold lifted January 25, 2019.
MGD009
Solid tumors
Phase 1 data due 1H 2020.
MGD013
Solid tumors
Phase 1 trial initiated 4Q 2018.
MGD019
Solid tumors
Phase 1 update due 1Q 2020.
MGD007 and MGA012
Colorectal Cancer
Phase 2/3 initial data due 2H 2020.
Margetuximab and MGA012 (MAHOGANY)
Gastric cancer
Phase 2 IND to be filed 2020.
Enoblituzumab
Head and neck cancer

Latest News

  1. MacroGenics to Present at the J.P. Morgan Healthcare Conference

    Rockville, MD, Jan. 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  2. MacroGenics Outlines Corporate Priorities for 2020

    Rockville, MD, Jan. 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  3. MacroGenics Announces Submission of Margetuximab Biologics License Application to U.S. FDA

    ROCKVILLE, MD, Dec. 19, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  4. MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

    Rockville, MD, Dec. 11, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  5. MacroGenics Presents Flotetuzumab Data in Patients with Primary Induction Failure and Early Relapsed Acute Myeloid Leukemia at the 2019 ASH Annual Meeting

    Rockville, MD, Dec. 09, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  6. MacroGenics to Participate in the Evercore ISI HealthCONx Conference

    Rockville, MD, Dec. 02, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  7. MacroGenics to Participate in Upcoming Investor Conferences

    Rockville, MD, Nov. 07, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  8. MacroGenics Provides Update on Corporate Progress and Third Quarter 2019 Financial Results

    ROCKVILLE, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  9. MacroGenics Announces Flotetuzumab Presentations at the ASH Annual Meeting 2019

    ROCKVILLE, MD, Nov. 06, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  10. MacroGenics Announces Date of Third Quarter 2019 Financial Results Conference Call

    Rockville, MD, Oct. 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  11. MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer

    ROCKVILLE, MD, Oct. 22, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  12. MacroGenics Presents Margetuximab Data in Gastroesophageal Cancer at the ESMO 2019 Congress

    ROCKVILLE, MD, Sept. 30, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for

  13. MacroGenics to Participate in Cantor Global Healthcare Conference

    ROCKVILLE, MD, Sept. 26, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  14. MacroGenics to Participate in Upcoming Investor Conferences

    ROCKVILLE, MD, Aug. 29, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics

  15. INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigati